Details for Patent: 8,293,756
✉ Email this page to a colleague
Which drugs does patent 8,293,756 protect, and when does it expire?
Patent 8,293,756 protects TASIGNA and is included in one NDA.
Protection for TASIGNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-one patent family members in thirty-four countries.
Summary for Patent: 8,293,756
| Title: | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
| Abstract: | A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process. |
| Inventor(s): | Nathalie Bruneau |
| Assignee: | Novartis AG |
| Application Number: | US12/442,544 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,293,756 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 8,293,756
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-003 | Mar 22, 2018 | AB | RX | Yes | No | 8,293,756*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-002 | Jun 17, 2010 | AB | RX | Yes | No | 8,293,756*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Novartis | TASIGNA | nilotinib hydrochloride | CAPSULE;ORAL | 022068-001 | Oct 29, 2007 | AB | RX | Yes | Yes | 8,293,756*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,293,756
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 06121371 | Sep 27, 2006 | |
| PCT Information | |||
| PCT Filed | September 25, 2007 | PCT Application Number: | PCT/EP2007/060165 |
| PCT Publication Date: | April 03, 2008 | PCT Publication Number: | WO2008/037716 |
International Family Members for US Patent 8,293,756
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 062980 | ⤷ Start Trial | |||
| Australia | 2007301977 | ⤷ Start Trial | |||
| Brazil | PI0719438 | ⤷ Start Trial | |||
| Canada | 2662571 | ⤷ Start Trial | |||
| Chile | 2007002766 | ⤷ Start Trial | |||
| China | 101516344 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
